Hologic's growth continues in Q2

By LabPulse.com staff writers

April 29, 2021 -- Hologic has continued to post significant increases in revenue, with revenues doubling in the company's second quarter. The growth was driven primarily by demand for the company's SARS-CoV-2 assays, but revenues in Hologic's Breast Health business also increased.

For the second quarter (end-March 27), Hologic recorded overall revenues of approximately $1.538 billion, up 103.4% compared with $756.1 million in the same quarter last year. The company posted net income under generally accepted accounting principles (GAAP) of $619.4 million, compared with $94.8 million in the same period last year.

The overall growth was driven primarily by increases in the company's worldwide molecular diagnostics revenue. Sales in the company's Diagnostics business climbed to $1.065 billion, up 233.4% over last year. The company reported the increase is driven by demand for its SARS-CoV-2 assays and Panther and Panther Fusion systems.

Revenues on the company's Breast Health side increased for the quarter to $336.3 million, up 9.3% from $307.8 million in the second quarter of 2020.

Hologic completed three acquisitions in the second quarter. It acquired Somatex in December for about $63 million, Biotheranostic in February for approximately $232 million, and Diagenode in March for approximately $153 million.

Hologic acquires Mobidiag for $795M
Hologic announced it has agreed to acquire Mobidiag, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests...
Hologic acquires Diagenode for $159 million
Hologic has purchased European molecular diagnostic assay and epigenetic product developer Diagenode for $159 million in a deal that will expand...
Hologic wraps up Biotheranostics acquisition
Hologic has completed the acquisition of cancer test developer Biotheranostics. Hologic is gaining access to two laboratory-developed tests as part of...
Hologic inks deal with Google to unite cloud with diagnostics
Hologic has announced a collaboration with Google designed to advance the potential of digital diagnostics for cervical cancer screening by making Google...
Diagnostics growth drives Hologic's Q1 results higher
Strong growth in its molecular diagnostics business -- with revenues almost tripling due to the COVID-19 pandemic -- helped drive first-quarter preliminary...

Copyright © 2021 LabPulse.com

Last Updated mf 4/29/2021 10:42:01 AM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current